NCT05746481View on ClinicalTrials.gov

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

August 19, 2024

Study Completion Date

August 31, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Tiragolumab

Tiragolumab (an investigational novel immune checkpoint inhibitor): 600 mg IV for induction treatment administered on Day 1 of each 21-day cycle for 4 cycles. Maintenance therapy will continue with tiragolumab on Day 1 of each 21-day cycle.

DRUG

Atezolizumab

Atezolizumab (monoclonal antibody): 1200 mg IV administered on Day 1 of each 21-day cycle.

DRUG

Pemetrexed

Pemetrexed (antifolate antineoplastic agent chemotherapy): 500 mg/m2 administered IV on Day 1 of each 21-day cycle.

DRUG

Carboplatin

Carboplatin AUC 5 (alkylating agent chemotherapy): injection administered on Day 1 of each 21-day cycle.

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Liza Villaruz, MD

OTHER